Opus Point Partners Management as of March 31, 2016
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 52 positions in its portfolio as reported in the March 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| iShares Russell 2000 Index (IWM) | 17.1 | $22M | 200k | 110.63 | |
| Bristol Myers Squibb (BMY) | 3.8 | $4.9M | 77k | 63.88 | |
| Medivation | 3.8 | $4.9M | 106k | 45.98 | |
| Alnylam Pharmaceuticals (ALNY) | 3.8 | $4.9M | 78k | 62.78 | |
| Merck & Co (MRK) | 3.7 | $4.8M | 90k | 52.91 | |
| Amgen (AMGN) | 3.1 | $4.1M | 27k | 149.94 | |
| BioMarin Pharmaceutical (BMRN) | 3.1 | $4.0M | 48k | 82.47 | |
| Celgene Corporation | 3.1 | $4.0M | 40k | 100.09 | |
| Nektar Therapeutics (NKTR) | 3.1 | $4.0M | 288k | 13.75 | |
| Ionis Pharmaceuticals (IONS) | 3.0 | $3.9M | 97k | 40.50 | |
| Seattle Genetics | 3.0 | $3.9M | 110k | 35.09 | |
| Incyte Corporation (INCY) | 2.9 | $3.7M | 52k | 72.47 | |
| Alexion Pharmaceuticals | 2.7 | $3.5M | 25k | 139.22 | |
| Illumina (ILMN) | 2.7 | $3.5M | 22k | 162.09 | |
| Alkermes (ALKS) | 2.7 | $3.5M | 102k | 34.19 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.5 | $3.3M | 41k | 79.49 | |
| Mettler-Toledo International (MTD) | 2.5 | $3.3M | 9.5k | 344.74 | |
| Pfizer (PFE) | 2.5 | $3.3M | 110k | 29.64 | |
| Regeneron Pharmaceuticals (REGN) | 2.5 | $3.2M | 8.9k | 360.40 | |
| Qiagen | 2.3 | $3.0M | 135k | 22.34 | |
| Biogen Idec (BIIB) | 2.2 | $2.9M | 11k | 260.31 | |
| Proshares Tr pshs ult nasb (BIB) | 2.0 | $2.6M | 65k | 40.88 | |
| Epizyme | 1.8 | $2.3M | 190k | 12.12 | |
| AstraZeneca (AZN) | 1.7 | $2.2M | 79k | 28.15 | |
| Agios Pharmaceuticals (AGIO) | 1.6 | $2.1M | 51k | 40.61 | |
| Pacira Pharmaceuticals (PCRX) | 1.4 | $1.9M | 35k | 52.98 | |
| Vericel (VCEL) | 1.4 | $1.8M | 299k | 5.86 | |
| Clovis Oncology | 1.1 | $1.4M | 75k | 19.20 | |
| Hologic (HOLX) | 1.0 | $1.3M | 39k | 34.50 | |
| Medicines Company | 1.0 | $1.3M | 41k | 31.78 | |
| Loxo Oncology | 0.8 | $984k | 36k | 27.33 | |
| New Senior Inv Grp | 0.7 | $927k | 90k | 10.30 | |
| Spark Therapeutics | 0.7 | $930k | 32k | 29.52 | |
| Proshs Ultrashrt S&p500 Prosha etf | 0.7 | $853k | 45k | 18.96 | |
| Ultragenyx Pharmaceutical (RARE) | 0.7 | $855k | 14k | 63.33 | |
| Adamas Pharmaceuticals | 0.6 | $781k | 54k | 14.46 | |
| Flamel Technologies | 0.6 | $763k | 69k | 11.04 | |
| Achillion Pharmaceuticals | 0.6 | $764k | 99k | 7.72 | |
| Merrimack Pharmaceuticals In | 0.6 | $753k | 90k | 8.37 | |
| Paratek Pharmaceuticals | 0.5 | $683k | 45k | 15.18 | |
| Seres Therapeutics (MCRB) | 0.5 | $645k | 24k | 26.54 | |
| Zogenix | 0.5 | $630k | 68k | 9.25 | |
| Dicerna Pharmaceuticals | 0.5 | $579k | 108k | 5.36 | |
| Ignyta | 0.4 | $548k | 81k | 6.77 | |
| Ophthotech | 0.4 | $533k | 13k | 42.30 | |
| pSivida | 0.4 | $482k | 180k | 2.68 | |
| Karyopharm Therapeutics (KPTI) | 0.3 | $442k | 50k | 8.93 | |
| United Therapeutics Corporation (UTHR) | 0.3 | $429k | 3.8k | 111.49 | |
| D Fluidigm Corp Del (LAB) | 0.3 | $363k | 45k | 8.07 | |
| Direxion Shs Etf Tr sp biotch bl | 0.2 | $329k | 12k | 27.44 | |
| Gilead Sciences (GILD) | 0.2 | $301k | 3.3k | 91.71 | |
| Axovant Sciences | 0.2 | $303k | 26k | 11.47 |
